Logo image of AADI

AADI BIOSCIENCE INC (AADI) Stock Fundamental Analysis

NASDAQ:AADI - Nasdaq - US00032Q1040 - Common Stock - Currency: USD

2.05  -0.05 (-2.38%)

After market: 2.06 +0.01 (+0.49%)

Fundamental Rating

2

Taking everything into account, AADI scores 2 out of 10 in our fundamental rating. AADI was compared to 560 industry peers in the Biotechnology industry. The financial health of AADI is average, but there are quite some concerns on its profitability. AADI does not seem to be growing, but still is valued expensively.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

In the past year AADI has reported negative net income.
AADI had a negative operating cash flow in the past year.
AADI had negative earnings in each of the past 5 years.
In the past 5 years AADI always reported negative operating cash flow.
AADI Yearly Net Income VS EBIT VS OCF VS FCFAADI Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 -20M -40M -60M -80M -100M

1.2 Ratios

AADI has a Return On Assets of -71.98%. This is in the lower half of the industry: AADI underperforms 65.44% of its industry peers.
AADI has a Return On Equity of -89.57%. This is comparable to the rest of the industry: AADI outperforms 48.95% of its industry peers.
Industry RankSector Rank
ROA -71.98%
ROE -89.57%
ROIC N/A
ROA(3y)-50.74%
ROA(5y)-44.04%
ROE(3y)-60.48%
ROE(5y)-51.04%
ROIC(3y)N/A
ROIC(5y)N/A
AADI Yearly ROA, ROE, ROICAADI Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 5K 10K

1.3 Margins

The Gross Margin of AADI (87.39%) is better than 88.95% of its industry peers.
AADI does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 87.39%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
AADI Yearly Profit, Operating, Gross MarginsAADI Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 -2K -4K -6K -8K

More info and screens

6

2. Health

2.1 Basic Checks

AADI does not have a ROIC to compare to the WACC, probably because it is not profitable.
AADI has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
AADI Yearly Shares OutstandingAADI Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 5M 10M 15M 20M
AADI Yearly Total Debt VS Total AssetsAADI Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 50M 100M 150M

2.2 Solvency

Based on the Altman-Z score of -3.05, we must say that AADI is in the distress zone and has some risk of bankruptcy.
With a Altman-Z score value of -3.05, AADI perfoms like the industry average, outperforming 48.25% of the companies in the same industry.
There is no outstanding debt for AADI. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -3.05
ROIC/WACCN/A
WACC10.38%
AADI Yearly LT Debt VS Equity VS FCFAADI Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 50M -50M 100M 150M

2.3 Liquidity

A Current Ratio of 4.89 indicates that AADI has no problem at all paying its short term obligations.
With a Current ratio value of 4.89, AADI perfoms like the industry average, outperforming 53.68% of the companies in the same industry.
AADI has a Quick Ratio of 4.54. This indicates that AADI is financially healthy and has no problem in meeting its short term obligations.
AADI has a Quick ratio (4.54) which is in line with its industry peers.
Industry RankSector Rank
Current Ratio 4.89
Quick Ratio 4.54
AADI Yearly Current Assets VS Current LiabilitesAADI Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 50M 100M 150M

More info and screens

1

3. Growth

3.1 Past

The Earnings Per Share has been growing slightly by 3.69% over the past year.
EPS 1Y (TTM)3.69%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-11.67%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%14.43%

3.2 Future

Based on estimates for the next years, AADI will show a very strong growth in Earnings Per Share. The EPS will grow by 33.74% on average per year.
The Revenue is expected to decrease by -14.87% on average over the next years. This is quite bad
EPS Next Y71.14%
EPS Next 2Y23.74%
EPS Next 3Y15.15%
EPS Next 5Y33.74%
Revenue Next Year-46.53%
Revenue Next 2Y-24.02%
Revenue Next 3Y38.79%
Revenue Next 5Y-14.87%

3.3 Evolution

AADI Yearly Revenue VS EstimatesAADI Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2018 2020 2021 2022 2023 2024 2025 2026 2027 2031 2032 20M 40M 60M
AADI Yearly EPS VS EstimatesAADI Yearly EPS VS EstimatesYearly EPS VS Estimates 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 0 5 -5

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

AADI reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year AADI is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
AADI Price Earnings VS Forward Price EarningsAADI Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
AADI Per share dataAADI EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 1 -1 -2

4.3 Compensation for Growth

A more expensive valuation may be justified as AADI's earnings are expected to grow with 15.15% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y23.74%
EPS Next 3Y15.15%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for AADI!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

AADI BIOSCIENCE INC

NASDAQ:AADI (3/18/2025, 8:20:08 PM)

After market: 2.06 +0.01 (+0.49%)

2.05

-0.05 (-2.38%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)03-18 2025-03-18/amc
Earnings (Next)05-06 2025-05-06/bmo
Inst Owners61.01%
Inst Owner Change129.46%
Ins Owners11.42%
Ins Owner Change38.98%
Market Cap94.85M
Analysts47.5
Price Target3.06 (49.27%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly Dividend0
Dividend Growth(5Y)N/A
DP0%
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)12.35%
Min EPS beat(2)1.43%
Max EPS beat(2)23.27%
EPS beat(4)3
Avg EPS beat(4)7.54%
Min EPS beat(4)-3.76%
Max EPS beat(4)23.27%
EPS beat(8)6
Avg EPS beat(8)9.48%
EPS beat(12)9
Avg EPS beat(12)8.71%
EPS beat(16)12
Avg EPS beat(16)6.92%
Revenue beat(2)1
Avg Revenue beat(2)2.47%
Min Revenue beat(2)-2.25%
Max Revenue beat(2)7.19%
Revenue beat(4)1
Avg Revenue beat(4)-3.79%
Min Revenue beat(4)-18.68%
Max Revenue beat(4)7.19%
Revenue beat(8)3
Avg Revenue beat(8)-1.69%
Revenue beat(12)7
Avg Revenue beat(12)204.18%
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)0%
EPS NQ rev (3m)10.2%
EPS NY rev (1m)8.11%
EPS NY rev (3m)-7.94%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)0.68%
Revenue NY rev (1m)0.04%
Revenue NY rev (3m)-1.52%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 3.78
P/FCF N/A
P/OCF N/A
P/B 1.38
P/tB 1.38
EV/EBITDA N/A
EPS(TTM)-2.35
EYN/A
EPS(NY)-0.68
Fwd EYN/A
FCF(TTM)-1.22
FCFYN/A
OCF(TTM)-1.17
OCFYN/A
SpS0.54
BVpS1.49
TBVpS1.49
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -71.98%
ROE -89.57%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 87.39%
FCFM N/A
ROA(3y)-50.74%
ROA(5y)-44.04%
ROE(3y)-60.48%
ROE(5y)-51.04%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score3
Asset Turnover0.29
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 1232.43%
Cap/Sales 9.09%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 4.89
Quick Ratio 4.54
Altman-Z -3.05
F-Score3
WACC10.38%
ROIC/WACCN/A
Cap/Depr(3y)890.25%
Cap/Depr(5y)600.82%
Cap/Sales(3y)7.89%
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)3.69%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-11.67%
EPS Next Y71.14%
EPS Next 2Y23.74%
EPS Next 3Y15.15%
EPS Next 5Y33.74%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%14.43%
Revenue Next Year-46.53%
Revenue Next 2Y-24.02%
Revenue Next 3Y38.79%
Revenue Next 5Y-14.87%
EBIT growth 1Y8.77%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-10.26%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-6.68%
OCF growth 3YN/A
OCF growth 5YN/A